The FDA has approved pembrolizumab (Keytruda, Merck) for the treatment of adults and children with unresectable or metastatic solid tumors with a microsatellite instability–high or mismatch repair–deficient biomarker. This indication includes patients with solid tumors—such as colorectal and other GI tumors, and endometrial cancer—that have progressed following prior treatment and who have no satisfactory alternative treatment options and patients with colorectal cancer
JULY 24, 2017